Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.53 |
| ▸ | HPGDS | O60760 | 2/20 | 0.52 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.51 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.51 |
| ▸ | NNMT | P40261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | KHK | P50053 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960460 | 0.88 | HCAR3 (0.60) | SMYD3HPGDSHCAR3ALDH1A1HPGD | |
| SCHEMBL2962909 | 0.86 | HCAR3 (0.55) | SMYD3HPGDSHCAR3SSTR5ALDH1A1 | |
| SCHEMBL2964744 | 0.81 | SMYD3 (0.54) | SMYD3HPGDSALDH1A1EGLN1KHK | |
| SCHEMBL2963992 | 0.81 | SMYD3 (0.54) | SMYD3HPGDSSSTR5NNMTEGLN1 | |
| SCHEMBL28803756 | 0.81 | SSTR5 (0.51) | HPGDSHCAR3SSTR5NNMTALDH1A1 | |
| SCHEMBL14190691 | 0.76 | HPGDS (0.62) | SMYD3HPGDSEGLN1KHK | |
| SCHEMBL279571 | 0.75 | RAB9A (0.71) | SMYD3ALDH1A1HPGDHDAC4HDAC6 | |
| SCHEMBL12277201 | 0.74 | HCAR3 (0.79) | SMYD3HCAR3 | |
| SCHEMBL18715411 | 0.74 | HCAR3 (0.70) | HCAR3NNMTHPGDTSHRHDAC6 | |
| SCHEMBL4233677 | 0.74 | HCAR3 (0.56) | HPGDSHCAR3ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772253-B2 | Amide derivatives as somatostatin receptor 5 antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1893603-B1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| CN-101189226-A | Piperidin-4-yl-amide derivatives and their use as SST receptor subtype 5 antagonists | HOFFMANN LA ROCHE (CH) | 2008-05-28 | — | — | CN | disclosed |
| EP-1893603-A1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006128803-A1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | WO | disclosed |
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | SSTR5, SSTR3, SSTR1 | SMYD3 2731/4885HPGDS 2883/4885HCAR3 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.